MDSCs sneak CSCs out of (immuno)surveillance

Carlos Jiménez-Cortegana; Claudia Galassi; Lorenzo Galluzzi

doi:10.1016/j.it.2021.11.008

MDSCs sneak CSCs out of (immuno)surveillance

Trends Immunol. 2022 Jan;43(1):1-3. doi: 10.1016/j.it.2021.11.008. Epub 2021 Dec 2.

Authors

Carlos Jiménez-Cortegana¹, Claudia Galassi², Lorenzo Galluzzi³

Affiliations

¹ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; Department of Medical Biochemistry, Molecular Biology, and Immunology, Faculty of Medicine, University of Seville, Seville, Spain; Clinical Biochemistry, Virgen Macarena University Hospital, Seville, Spain.
² Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
³ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; Sandra and Edward Meyer Cancer Center, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA. Electronic address: deadoc80@gmail.com.

PMID: 34863632
DOI: 10.1016/j.it.2021.11.008

Abstract

Cancer stem cells (CSCs) are known for their superior tumor-initiating and tumor-repopulating potential, partly reflecting their pronounced ability to evade immune recognition. Liu and colleagues recently identified a new aldehyde dehydrogenase (ALDH)-dependent mechanism whereby triple-negative breast CSCs evade immunosurveillance upon recruitment of myeloid-derived suppressor cells.

Keywords: GM-CSF; MAPK signaling; NF-κB; gemcitabine; immune checkpoint inhibitors; intracellular pH.

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Aldehyde Dehydrogenase
Humans
Myeloid-Derived Suppressor Cells*
Neoplasms*
Neoplastic Stem Cells

Substances

Aldehyde Dehydrogenase